N-Ethyl-N-methylcarbamoyl Chloride

We are N-Ethyl-N-methylcarbamoyl Chloride CAS:42252-34-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:   N-Ethyl-N-methylcarbamoyl Chloride
CAS.NO:  42252-34-6
Synonyms:
N-Ethyl-N-methylcarbamoylchloride
N-ethyl-N-methylcarbamoyl chloride

Molecular Formula:C4H8ClNO
Molecular Weight: 121.56500

Physical and Chemical Properties:
Density: 1.101 g / cm3
Boiling point: 165.1ºC at 760 mmHg
Melting point: /
Flash point: 53.7ºC
Refractive index: 1.441

Specification:
Appearance: Colorless liquid
Purity:≥98%
Total Impurities:≤1.50%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Rivastigmine tartrate CAS:129101-54-8
Intermediates of Rivastigmine CAS:123441-03-2

Related News: The unit of the British drugmaker, which is challenging HIV drug market leader Gilead Sciences, said it will work with the FDA to determine the next steps for the new drug application.2,4,6,8-tetrakis(ethenyl)-2,4,6,8-tetramethyl-1,3,5,7,2,4,6,8-tetraoxatetrasilocane CAS:2554-06-5 The unit of the British drugmaker, which is challenging HIV drug market leader Gilead Sciences, said it will work with the FDA to determine the next steps for the new drug application.3-(5-bromo-2-phenylmethoxyphenyl)-3-phenylpropan-1-ol Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow become dysfunctional and thus produce an inadequate number of circulating blood cells.2-Bromoethyl acetate Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow become dysfunctional and thus produce an inadequate number of circulating blood cells.The drug substance is an active product that has completed the synthetic route, and the intermediate is a product in one place in the synthetic route.